144 related articles for article (PubMed ID: 31479720)
1. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.
Zhou L; Sharma P; Yeo KR; Higashimori M; Xu H; Al-Huniti N; Zhou D
Eur J Pharm Sci; 2019 Nov; 139():105061. PubMed ID: 31479720
[TBL] [Abstract][Full Text] [Related]
2. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
[TBL] [Abstract][Full Text] [Related]
4. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
Feng S; Cleary Y; Parrott N; Hu P; Weber C; Wang Y; Yin OQ; Shi J
Eur J Clin Pharmacol; 2015 May; 71(5):617-24. PubMed ID: 25801493
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
Higashimori M; Shimada H; Ichikawa K; Zhou D
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
[TBL] [Abstract][Full Text] [Related]
6. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations.
Wu X; Zhang H; Miah MK; Caritis SN; Venkataramanan R
J Clin Pharmacol; 2020 Apr; 60(4):477-488. PubMed ID: 31750550
[TBL] [Abstract][Full Text] [Related]
8. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
Cho CK; Ko E; Mo JY; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Jan; 47(1):82-94. PubMed ID: 38150171
[TBL] [Abstract][Full Text] [Related]
9. Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.
Chiba K; Shimizu K; Kato M; Nishibayashi T; Terada K; Izumo N; Sugiyama Y
Drug Metab Pharmacokinet; 2014; 29(5):379-86. PubMed ID: 24739523
[TBL] [Abstract][Full Text] [Related]
10. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
11. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
[TBL] [Abstract][Full Text] [Related]
12. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
[TBL] [Abstract][Full Text] [Related]
13. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
14. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
Lu S; Nand RA; Yang JS; Chen G; Gross AS
Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
